secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2022-04-11T23:59:59+00:00
Accession:  0000950170-22-005536
Event type: debt
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix raises $11.7M via private placement; amends 2021 term loan with SVB
----------------------------------------------------------------------------

- Sold 6,508,376 shares at $1.79/share to consortium including board members, raising ~$11.7M.
- Third Amendment to 2021 Term Loan: repays $3M in April 2022 and $2M later; waives Q1 2022 minimum revenue requirement.
- Waiver of prepayment fee on $3M repayment; consent for $2M milestone payment under Integrated Diagnostics purchase agreement.
- Reaffirms 2022 revenue guidance of $37.5M-$39.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017022005536/0000950170-22-005536-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017022005536/bdsx-20220407.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-005536

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer